Log in
Enquire now
MolMed

MolMed

MolMed, now part of AGC Biologics, was a biotechnology company developing anti-cancer therapies.

OverviewStructured DataIssuesContributors

Contents

agcbio.com
Is a
Company
Company
Organization
Organization

Company attributes

Industry
Immunotherapy
Immunotherapy
Cell therapy
Cell therapy
Stem cell
Stem cell
Healthcare
Healthcare
Biomedical engineering
Biomedical engineering
Technology
Technology
Biology
Biology
...
Location
Milan
Milan
0
B2X
B2B
B2B
CEO
‌
Riccardo Palmisano
0
Founder
‌
Riccardo Palmisano
Pitchbook URL
pitchbook.com/profiles...107627-32
Legal Name
Molecular Medicine S.p.A.0
Parent Organization
‌
Fininvest
0
Legal classification
Joint-stock company
Joint-stock company
Date Incorporated
1996
Number of Employees (Ranges)
51 – 200
Email Address
info@molmed.com0
Phone Number
+39022127710
Number of Employees
223
Full Address
Via Olgettina, 58 20132 Milano, Italy0
Founded Date
1996
Competitors
OnQuality Pharmaceuticals
OnQuality Pharmaceuticals
Board of Directors
‌
Riccardo Palmisano
Key People
‌
Riccardo Palmisano
Acquisition Transaction
‌
Acquisition of MolMed by AGC Biologics
Also Known As
Molecular Medicine0
Patents Assigned (Count)
8
Country
Italy
Italy
0
Headquarters
Milan
Milan
0

Other attributes

Company Operating Status
Active
Overview

MolMed was a clinical stage biotechnology company focused on research, development, manufacturing, and clinical validation of innovative therapies, including gene and cell therapies for the treatment of cancer and rare diseases. The company was one of the first in Europe to have obtained the GMP manufacturing authorization for cell and gene therapies ex vivo for both the company's proprietary products and for third-party products. MolMed worked on its own products and worked as a contracted manufacturer for companies developing gene and cell therapy products.

MolMed's proprietary product, Zalmoxis, was a cell therapy based on donor T cells genetically engineered to enable bone marrow transplants from partially compatible donors to help patients with high-risk hematological malignancies in order to reduce or completely eliminate post-transplant immunosuppression prophylaxis and inducing immune reconstitution. MolMed was also developing a therapeutic platform based on Chimeric Antigen Receptor (CAR), both autologous and allogeneic.

Acquisition

In July 2020, MolMed was acquired by AGC Biologics, a global biopharmaceutical contract development and manufacturing organization (CDMO). As MolMed was a listed company at the time, AGC acquired the company through a tender offer for the shares of the company, completed in September 2020, at which point MolMed was delisted from the Milan Stock Exchange and became a part of AGC Biologics. The acquisition of MolMed allowed AGC Biologics to offer end-to-end cell and gene therapy CDMO services.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date

MolMed and AbCheck sign a three-year Master Agreement for the development of new CARs targeting novel tumor antigens

Affrimed

https://www.globenewswire.com/news-release/2018/06/28/1531181/0/en/MolMed-and-AbCheck-sign-a-three-year-Master-Agreement-for-the-development-of-new-CARs-targeting-novel-tumor-antigens.html

Web

Will the Leading Italian Biotech soon have its First Cell therapy on the Market?

DENISE NEVES GAMEIRO

https://labiotech.eu/medical/molmed-zalmoxis-cell-therapy-ema-approval-hstc/

Web

References

Find more companies like MolMed

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.